Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Hepion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get HEPA alerts

About John Brancaccio

John Brancaccio is recorded as CFO at Hepion Pharmaceuticals, Inc. (HEPA) since August 6, 2024 and Chairman at Hepion Pharmaceuticals, Inc. (HEPA) since February 20, 2024. Hepion Pharmaceuticals, Inc. reported in an 8-K filed June 30, 2025 that John Brancaccio resigned as director, effective June 30, 2025. Hepion Pharmaceuticals, Inc. reported in an 8-K filed June 30, 2025 that John Brancaccio resigned as CFO, effective June 30, 2025. Hepion Pharmaceuticals, Inc. reported in an 8-K filed August 7, 2024 that John Brancaccio was appointed interim Chief Executive Officer, effective August 6, 2024. Equibles holds 4 filed executive changes naming John Brancaccio; each is listed under recent activity with its source filing. Hepion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Hepion Pharmaceuticals, Inc. includes Dr. Kaouthar Lbiati (CEO), Gary Stetz (CEO, CFO and Board Member), John Cavan (CEO and CFO) and 7 others.

“On June 25, 2025, John Brancaccio, the CFO and a director of Hepion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), resigned as CFO and a director, effective June 30, 2025 for personal reasons.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed June 30, 2025 · Read the filing
“On June 25, 2025, John Brancaccio, the CFO and a director of Hepion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), resigned as CFO and a director, effective June 30, 2025 for personal reasons.”
Hepion Pharmaceuticals, Inc. Form 8-K, filed June 30, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Hepion Pharmaceuticals, Inc.

Recent activity